Rna Diagnostics' News - New research shows RDA valuable in guiding chemotherapy treatment by predicting breast cancer survivability, RnaDx' Toronto office relocates.


Winter 2014

RDA™ predicts breast cancer survival

Rna Diagnostics' RNA Disruption Assay™ (RDA™) can be highly useful in guiding chemotherapy treatment for women with breast cancer, based on research presented at the San Antonio Breast Cancer Symposium (SABCS).

Dr. Amadeo Parissenti, Chief Scientific Officer at Rna Diagnostics and Professor, Laurentian University, presented with colleagues, “High tumor RNA disruption is associated with increased survival in patients with locally advanced breast cancer”.

The findings, based on the NCIC MA.22 clinical trial of locally advanced breast cancer patients, showed that response to neo-adjuvant chemotherapy as determined by RDA™ early in treatment correlates highly with increased Disease Free Survival (DFS) at 5 years. Patients assessed by the RDA™ test during chemotherapy treatment as non-responders achieved considerably reduced DFS compared to patients assessed as responders. Non-responders had a mean DFS of 33 months survival versus 57 months for patients identified as responders. The RDA test stratifies chemotherapy breast cancer patients by disease free survival irrespective of tumour subtype.

Dr. Kenneth Pritzker, CEO of Rna Diagnostics, said “This study demonstrates that RDA™ can stratify patients by response to chemotherapy treatment early enough during treatment to guide modifications to the treatment delivered.  By this very important criteria RDA appears superior to the standard prognostic biomarker, pathologic Complete Response (pCR).” 

RnaDx Toronto team relocates

Rna Diagnostics' Toronto office has moved to the Banting Institute on College Street. 

Left to right: Dr. Ken Pritzker, President & CEO, Laura Pritzker, Principal Scientist, Sanaa Noubir, Clinical Development Manager, Xiaohui Wang, Research Associate, John Connolly, VP Corporate Development, John Jordan, Chief Financial Officer

Dr. Amadeo Parissenti, Chief Scientific Officer for Rna Diagnostics, in the company's Sudbury Laboratory.

In the News

CBC Morning North radio published an interview with Chief Scientific Officer Dr. Amadeo Parissenti.

Rna Diagnostics’ Clinical Development Manager, Dr. Sanaa Noubir was interviewed on CBON - CBC French radio Sudbury.  CBC also featured the research on their website.

Northern Life and the Sudbury Star profiled Dr. Parissenti and the RnaDx research.
CTV Northern Ontario: News at Noon featured Dr. Parissenti and his Sudbury research team. Watch the television clip.  

Management Team

Ken Pritzker, MD, FRCPC
President & CEO
Amadeo Parissenti, PhD
Chief Scientific Officer
John Connolly, MBA
VP Corporate Development
John Jordan, MBA, CMA
Chief Financial Officer
Laura Pritzker, PhD
Principal Scientist

Clinical Advisory Board

Maureen E. Trudeau, MA, MD, FRCPC, Toronto, Canada
Gunter von Minckwitz, MD, PhD, Frankfurt, Germany
Michael Untch, MD, PhD, Berlin, Germany
Harry D. Bear, MD, PhD, Richmond, VA, USA

Rna Diagnostics Inc. is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management.

Our mailing address is:
Rna Diagnostics Inc.
MaRS Centre, Heritage Building, 101 College Street, Suite HL20-4, Toronto, ON, Canada
Toronto, ON M5G 1L7

Add us to your address book
For more information contact:
John Connolly
VP Corporate Development